Comparative Pharmacology
Head-to-head clinical analysis: FEMINONE versus PMB 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMINONE versus PMB 400.
FEMINONE vs PMB 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FEMINONE (progesterone) is a steroid hormone that binds to the progesterone receptor, modulating gene expression in target tissues. It transforms the endometrium from proliferative to secretory phase, reduces endometrial hyperplasia risk, and suppresses gonadotropin release via negative feedback.
PMB 400 is a combination of progesterone and micronized estradiol; progesterone suppresses gonadotropin secretion and transforms proliferative endometrium into secretory endometrium, while estradiol replaces endogenous estrogen production and promotes growth of reproductive tissues.
0.625 mg orally once daily
1 tablet (400 mg Pregabalin, 400 mg Mirogabalin, 100 mg Benfotiamine) orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 7-8 hours (range 5-12 h); clinical significance: steady-state reaches after ~2-3 days, necessitates daily dosing for contraceptive efficacy.
Terminal elimination half-life is 12-16 hours in adults with normal renal function; may be prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Feminone (norethindrone) is primarily excreted in urine (approximately 70-80% as metabolites, with <5% as unchanged drug) and feces (20-30%).
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; hepatic metabolism via CYP3A4 produces inactive metabolites, with biliary/fecal excretion of metabolites (20-30%) and parent compound (<5%).
Category C
Category C
Estrogen
Estrogen/Progestin Combination